Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches (3rd Edition)

Dear Colleagues,

Renal cell carcinoma is a complex disease comprised of a variety of histological subtypes. The most common histological subtype is clear cell renal cell carcinoma (ccRCC), which accounts for 70–80% of kidney cancer. Recent diagnostic and therapeutic advances are improving the survival rate of kidney cancer patients. The loss of tumor suppressor genes and the activation of oncogenes both allow tumors to reprogram the pathways. A large number of biomarkers have been proposed for predicting RCC recurrence. Some molecular-targeted therapies, such as tyrosine kinase inhibitors, mTOR inhibitors, and immunotherapies, have dramatically improved the outcome of RCCs. Ultrasonography is the most frequently used imaging modality for the initial diagnosis of renal masses, but a multimodality imaging approach is routinely performed in RCC. The medical treatment of RCC has greatly evolved in recent years, thanks to new information regarding the molecular pathogenesis and its histology. However, acquired drug resistance and treatment for a prognostically unfavorable subgroup of ccRCCs and other histological subtypes remain major challenges. Novel biomarkers are highly desirable for the prediction of outcomes, for drug responses, and for a novel therapeutic target.

This Special Issue of Biomedicines focuses on recent discoveries concerning clinicopathological, physiological, and molecular approaches to diagnosis, classification, and novel multidisciplinary treatments. Considering the complexity of the molecular biological background of each histological subtype of renal cell carcinoma, we welcome contributions aimed at both major and emerging histological subtypes of renal cell carcinoma.

Dr. Silvio Maringhini
Dr. Riuko Ohashi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• renal cell carcinoma
• pathology
• physiology
• diagnosis
• multimodal treatment
• drug resistance
• biomarkers

• Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches in Biomedicines (11 articles)
• Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches 2.0 in Biomedicines (7 articles)